Randomized controlled trials (RCTs) are called the gold standard because they are the most reliable way to determine whether a treatment actually works. Every major evidence ranking system places them at or near the top, and regulatory agencies like the FDA require data from controlled clinical trials before approving new drugs. The reason comes down to one thing: RCTs are specifically designed to eliminate the biases that plague every other type of study.
What Randomization Actually Does
The core power of an RCT lies in random assignment. When researchers randomly sort participants into a treatment group and a control group, every person has an equal chance of ending up in either one. This seems simple, but it solves a problem that no other study design can fully address: it distributes both known and unknown differences between people evenly across the groups.
Think about what happens without randomization. If a doctor chooses which patients get a new drug, they might unconsciously give it to healthier patients or sicker patients. If patients choose for themselves, the ones who sign up for treatment might be more motivated, wealthier, or have milder disease. These differences, called confounders, can make a treatment look effective when it isn’t, or hide a real benefit. Randomization washes them out. Age, genetics, diet, stress levels, preexisting conditions, and factors nobody has even thought to measure all get spread roughly equally between the two groups. That means any difference in outcomes can be attributed to the treatment itself, not to something else.
How Blinding Prevents Subtle Bias
Randomization handles who gets the treatment. Blinding handles what people know about it. In a double-blind trial, neither the participants nor the researchers know who is receiving the real treatment and who is receiving a placebo. This prevents two separate problems. Participants who know they’re getting the active drug may feel better simply because they expect to (the placebo effect), and participants who know they’re in the control group may report worse outcomes out of disappointment. On the research side, doctors who know which group a patient belongs to might unconsciously evaluate them differently, look harder for side effects, or interpret ambiguous symptoms in a way that confirms their expectations. Blinding both sides removes these influences.
Where RCTs Sit in the Evidence Hierarchy
Medical decisions are ideally based on the best available evidence, and researchers have developed formal ranking systems to classify how trustworthy different types of studies are. In every major framework, including those from the Canadian Task Force on Periodic Health Examination, the system developed by David Sackett, and the Oxford Centre for Evidence-Based Medicine, RCTs occupy the highest tier for questions about whether treatments work. The only thing ranked higher is a systematic review that pools results from multiple RCTs.
Below RCTs sit cohort studies, which follow groups of people over time but don’t randomly assign treatment, and case-control studies, which look backward from an outcome to find possible causes. These designs are valuable, but they can’t fully account for confounding. Even after researchers statistically adjust for every risk factor they can measure, residual confounding from unmeasured or unknown factors can still distort results. This is the fundamental gap that randomization closes.
The Confounding-by-Indication Problem
One specific bias illustrates why observational studies struggle to match RCTs for treatment questions. Confounding by indication occurs when the very reason a patient receives a drug is also connected to their outcome. For example, patients prescribed a powerful blood thinner tend to be sicker than those who aren’t. If you simply compare outcomes between those two groups, the blood thinner might appear to cause worse results, when in reality the underlying illness is what’s driving the difference.
Researchers can try to correct for this statistically by adjusting for known risk factors, but the adjustments are only as good as the data available. Measurement error and unmeasured variables leave room for residual confounding. Randomization sidesteps the problem entirely: because group assignment is determined by chance, the reason a patient receives treatment is disconnected from their health status.
Why Regulators Require Them
The FDA requires data from at least two large, controlled clinical trials before a new drug can reach the market. This isn’t arbitrary. The history of medicine is full of treatments that looked promising in smaller or less rigorous studies but failed or caused harm when tested properly. The structured design of an RCT, with its protocol established before the trial begins, its predefined outcomes, and its controlled comparison group, gives regulators the clearest possible picture of whether a drug’s benefits outweigh its risks.
The modern RCT traces back to a 1948 British trial of streptomycin for tuberculosis, organized by the Medical Research Council. Austin Bradford Hill, a professor of medical statistics, helped design the study with random assignment to ensure unbiased comparison. That trial is widely regarded as a milestone in clinical research, and the principles it established still underpin drug approval processes worldwide.
Built-In Safeguards for Data Quality
RCTs come with several standardized practices that further protect the integrity of results. One is intention-to-treat analysis, which means every participant is analyzed in the group they were originally assigned to, regardless of whether they actually completed the treatment, switched groups, or dropped out. This preserves the balance created by randomization. If researchers only analyzed the patients who followed the protocol perfectly, they’d reintroduce bias: the type of person who sticks with a difficult treatment regimen is different from the type who drops out.
Another safeguard is the CONSORT statement, a 25-item checklist introduced in 1996 that standardizes how RCTs are reported in medical journals. It requires authors to describe their randomization method, blinding procedures, participant flow, and outcomes in a transparent, reproducible format. This makes it harder to selectively report only the results that look favorable and easier for other researchers to spot methodological problems.
What RCTs Can’t Do Well
For all their strengths, RCTs have real limitations, and understanding these is part of understanding why they’re the gold standard rather than the only standard.
The biggest concern is external validity, meaning whether results from a trial apply to patients in the real world. Trial participants are often highly selected. Eligibility criteria may exclude people with multiple health conditions, older adults, or those on other medications. Some trials use “run-in” periods where patients who experience side effects or don’t respond are removed before randomization even begins. In two trials of a heart failure drug, 6% to 9% of eligible patients were excluded during treatment run-in periods, mainly because of worsening symptoms or adverse events. The remaining participants were, by definition, people who tolerated the drug well. That’s useful for understanding the drug’s potential, but it doesn’t tell you what will happen when it’s prescribed broadly.
There’s also the issue of how trials measure success. Many use surrogate outcomes like lab values or imaging markers rather than simple clinical results that patients care about, such as feeling better or living longer. Surrogate outcomes are quicker and cheaper to measure, but they can be misleading. A drug might lower a blood marker without actually improving health. Even when trials do use clinical scales, the meaning of a small numerical improvement on a 100-point symptom score can be impossible to interpret in practical terms.
Finally, some important medical questions simply can’t be studied with RCTs. You can’t randomly assign people to smoke or not smoke, to experience trauma, or to go without a treatment that’s already known to save lives. The ethical foundation of any trial rests on what researchers call equipoise: genuine uncertainty in the medical community about which treatment is better. When that uncertainty doesn’t exist, randomization becomes unethical, and other study designs must fill the gap.
Why the Label Sticks
RCTs earn their reputation not because they’re perfect, but because no other single study design can isolate cause and effect as cleanly. Randomization neutralizes confounders that researchers can’t even identify. Blinding removes the subjective biases of both patients and clinicians. Standardized reporting and analysis rules make results transparent and reproducible. These features, working together, produce the most internally valid evidence available for answering the question that matters most in medicine: does this treatment work better than the alternative?